[Pancreatic pseudocyst after pegaspargase treatment in six children]

J B Sun1, Y H Huang2, H Chang2

  • 1Department of Pediatrics, Peking University Third Hospital, Beijing 100191, China.

Insights

Pediatric pancreatic pseudocyst following pegaspargase chemotherapy can be asymptomatic. Early diagnosis via imaging is crucial. Conservative management is preferred initially, with endoscopic drainage for enlarging cysts.

Area of Science:

  • Pediatric Gastroenterology
  • Oncology
  • Medical Imaging

Context:

  • Pegaspargase is a chemotherapy agent used in pediatric oncology.
  • Pancreatic pseudocysts are a potential complication of certain medical treatments.
  • This study focuses on a specific cohort of children treated at Peking University Third Hospital.

Purpose:

  • To investigate the clinical features and management strategies for pancreatic pseudocysts that develop after pegaspargase treatment in children.
  • To analyze the timeline from pegaspargase administration to pseudocyst diagnosis.
  • To evaluate the effectiveness and safety of different treatment modalities.

Summary:

  • Six pediatric cases of pancreatic pseudocyst post-pegaspargase were analyzed.
  • Abdominal pain was the primary symptom of pancreatitis.
  • Initially asymptomatic pseudocysts often enlarged under conservative care, necessitating endoscopic ultrasound-guided or ERCP-guided drainage.
  • Successful cyst resolution was achieved with endoscopic interventions, though one case required surgery.

Impact:

  • Highlights the importance of vigilant monitoring for pancreatic pseudocysts in children receiving pegaspargase.
  • Provides insights into the natural history and optimal treatment pathways for this complication.
  • Emphasizes the role of endoscopic procedures in managing pediatric pancreatic pseudocysts effectively.